BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1435 related articles for article (PubMed ID: 9153396)

  • 1. Regulation of p53 stability by Mdm2.
    Kubbutat MH; Jones SN; Vousden KH
    Nature; 1997 May; 387(6630):299-303. PubMed ID: 9153396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway.
    Chang YC; Lee YS; Tejima T; Tanaka K; Omura S; Heintz NH; Mitsui Y; Magae J
    Cell Growth Differ; 1998 Jan; 9(1):79-84. PubMed ID: 9438391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation.
    Jin Y; Lee H; Zeng SX; Dai MS; Lu H
    EMBO J; 2003 Dec; 22(23):6365-77. PubMed ID: 14633995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
    Xirodimas D; Saville MK; Edling C; Lane DP; Laín S
    Oncogene; 2001 Aug; 20(36):4972-83. PubMed ID: 11526482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts.
    Gentiletti F; Mancini F; D'Angelo M; Sacchi A; Pontecorvi A; Jochemsen AG; Moretti F
    Oncogene; 2002 Jan; 21(6):867-77. PubMed ID: 11840332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
    Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
    Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mdm2 binds p73 alpha without targeting degradation.
    Bálint E; Bates S; Vousden KH
    Oncogene; 1999 Jul; 18(27):3923-9. PubMed ID: 10435614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 and MDM2 are regulated by PI-3-kinases on multiple levels under stress induced by UV radiation and proteasome dysfunction.
    Latonen L; Kurki S; Pitkänen K; Laiho M
    Cell Signal; 2003 Jan; 15(1):95-102. PubMed ID: 12401524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.
    Brignone C; Bradley KE; Kisselev AF; Grossman SR
    Oncogene; 2004 May; 23(23):4121-9. PubMed ID: 15064742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathway regulating MDM2 protein degradation can be altered in human leukemic cells.
    Pan Y; Haines DS
    Cancer Res; 1999 May; 59(9):2064-7. PubMed ID: 10232588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MDM2-p53 interaction.
    Moll UM; Petrenko O
    Mol Cancer Res; 2003 Dec; 1(14):1001-8. PubMed ID: 14707283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ubiquitin ligase COP1 is a critical negative regulator of p53.
    Dornan D; Wertz I; Shimizu H; Arnott D; Frantz GD; Dowd P; O'Rourke K; Koeppen H; Dixit VM
    Nature; 2004 May; 429(6987):86-92. PubMed ID: 15103385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation.
    Zilfou JT; Hoffman WH; Sank M; George DL; Murphy M
    Mol Cell Biol; 2001 Jun; 21(12):3974-85. PubMed ID: 11359905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation.
    Okada Y; Osada M; Kurata S; Sato S; Aisaki K; Kageyama Y; Kihara K; Ikawa Y; Katoh I
    Exp Cell Res; 2002 Jun; 276(2):194-200. PubMed ID: 12027449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of p53 by Mdm2: fate is in the numbers.
    Shmueli A; Oren M
    Mol Cell; 2004 Jan; 13(1):4-5. PubMed ID: 14731389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways.
    Zhao L; Samuels T; Winckler S; Korgaonkar C; Tompkins V; Horne MC; Quelle DE
    Mol Cancer Res; 2003 Jan; 1(3):195-206. PubMed ID: 12556559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation.
    Zaika A; Marchenko N; Moll UM
    J Biol Chem; 1999 Sep; 274(39):27474-80. PubMed ID: 10488081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycyclic aromatic hydrocarbon carcinogens increase ubiquitination of p21 protein after the stabilization of p53 and the expression of p21.
    Nakanishi Y; Pei XH; Takayama K; Bai F; Izumi M; Kimotsuki K; Inoue K; Minami T; Wataya H; Hara N
    Am J Respir Cell Mol Biol; 2000 Jun; 22(6):747-54. PubMed ID: 10837373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53.
    Xirodimas DP; Stephen CW; Lane DP
    Exp Cell Res; 2001 Oct; 270(1):66-77. PubMed ID: 11597128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage.
    Joseph TW; Zaika A; Moll UM
    FASEB J; 2003 Sep; 17(12):1622-30. PubMed ID: 12958168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.